Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis

Gut

Volumn 63, Issue 6, 2014, Pages 984-995

  Cano, Carla E ^a   Hamidi, Tewfik ^a   Garcia, Maria Noé ^a   Grasso, Daniel ^a   Loncle, Céline ^a   Garcia, Stéphane ^a   Calvo, Ezequiel ^b   Lomberk, Gwen ^c,d   Dusetti, Nelson ^a   Bartholin, Laurent ^e   Urrutia, Raul ^c,d   Iovanna, Juan L ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b LAVAL UNIVERSITY   (Canada)

^c MAYO CLINIC   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; ARF PROTEIN; ASPARTIC ACID; CASPASE 3; CRE RECOMBINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEMCITABINE; GLYCINE; HEAT SHOCK PROTEIN; K RAS PROTEIN; LY 101 4B; NUCLEAR PROTEIN; NUCLEAR PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; WJQ 63;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL STRESS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE DELETION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE REPRESSION; HOMOZYGOSITY; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUPR1 GENE; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUASI MESENCHYMAL PANCREATIC DUCTAL ADENOCARCINOMA; TUMOR INVASION;

CANCER; ONCOGENES; PANCREAS; PANCREATIC CANCER; STRESS;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CADHERINS; CARCINOGENESIS; CASPASE 3; CELL SURVIVAL; CLAUDIN-1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GENES, SUPPRESSOR; HETEROZYGOTE; IMMEDIATE-EARLY PROTEINS; LIFE EXPECTANCY; MICE; MICE, KNOCKOUT; MUCIN-1; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 84899917831     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305221     Document Type: Article

References (64)

1. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72.
2. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-3.
3. Turrini O, Cano C, Legoffic A, et al. Genetic alterations in precancerous pancreatic lesions and their clinical implications. Gastroenterol Clin Biol 2009;33:1028-35, e1-9.
4. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994;145:1547-50. (Pubitemid 24378508)
5. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4. (Pubitemid 27199667)
6. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17:3112-26. (Pubitemid 38040774)
7. Grippo PJ, Nowlin PS, Demeure MJ, et al. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res 2003;63:2016-19. (Pubitemid 36538599)
8. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50. (Pubitemid 38050041)
9. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006;103:5947-52.
10. Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006;20:3130-46. (Pubitemid 44790628)
11. Hanlon L, Avila JL, Demarest RM, et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res 2010;70:4280-6.
12. Vincent DF, Yan KP, Treilleux I, et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 2009;5:e1000575.
13. Hill R, Calvopina JH, Kim C, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010;70:7114-24.
14. Shi G, Zhu L, Sun Y, et al. Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology 2009;136:1368-78.
15. Ijichi H, Chytil A, Gorska AE, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 2006;20:3147-60. (Pubitemid 44790629)
16. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83. (Pubitemid 40719130)
17. Ardito CM, Gruner BM, Takeuchi KK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012;22:304-17.
18. Navas C, Hernandez-Porras I, Schuhmacher AJ, et al. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012;22:318-30.
19. Mazur PK, Einwachter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2010;107:13438-43.
20. Hamidi T, Algul H, Cano CE, et al. Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. J Clin Invest 2012;122:2092-103.
21. Bratland A, Risberg K, Maelandsmo GM, et al. Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells. Cancer Res 2000;60:5578-83.
22. Mallo GV, Fiedler F, Calvo EL, et al. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J Biol Chem 1997;272:32360-9. (Pubitemid 28011918)
23. Vasseur S, Vidal Mallo G, Fiedler F, et al. Cloning and expression of the human p8, a nuclear protein with mitogenic activity. Eur J Biochem 1999;259:670-5. (Pubitemid 29075493)
24. Cano CE, Hamidi T, Sandi MJ, et al. Nupr1: the Swiss-knife of cancer. J Cell Physiol 2011;226:1439-43.
25. Goruppi S, Iovanna JL. Stress-inducible protein p8 is involved in several physiological and pathological processes. J Biol Chem 2010;285:1577-81.
26. Brannon KM, Million Passe CM, White CR, et al. Expression of the high mobility group A family member p8 is essential to maintaining tumorigenic potential by promoting cell cycle dysregulation in LbetaT2 cells. Cancer Lett 2007;254:146-55. (Pubitemid 47058814)
27. Carracedo A, Lorente M, Egia A, et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006;9:301-12.
28. Goruppi S, Patten RD, Force T, et al. Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. Mol Cell Biol 2007;27:993-1006. (Pubitemid 46174562)
29. Sambasivan R, Cheedipudi S, Pasupuleti N, et al. The small chromatin-binding protein p8 coordinates the association of anti-proliferative and pro-myogenic proteins at the myogenin promoter. J Cell Sci 2009;122:3481-91.
30. Kong DK, Georgescu SP, Cano C, et al. Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function. Mol Biol Cell 2010;21:1335-49.
31. Cano CE, Sandi MJ, Hamidi T, et al. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. EMBO Mol Med 2012;4:964-79.
32. Ito Y, Yoshida H, Motoo Y, et al. Expression of p8 protein in breast carcinoma; an inverse relationship with apoptosis. Anticancer Res 2005;25:833-7. (Pubitemid 40546851)
33. Ree AH, Pacheco MM, Tvermyr M, et al. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res 2000;6:1778-83. (Pubitemid 30305071)
34. Su SB, Motoo Y, Iovanna JL, et al. Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. Clin Cancer Res 2001;7:1320-4. (Pubitemid 32708687)
35. Su SB, Motoo Y, Iovanna JL, et al. Expression of p8 in human pancreatic cancer. Clin Cancer Res 2001;7:309-13. (Pubitemid 32184317)
36. Giroux V, Malicet C, Barthet M, et al. p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 2006;12:235-41. (Pubitemid 43166199)
37. Vasseur S, Hoffmeister A, Garcia-Montero A, et al. Mice with targeted disruption of p8 gene show increased sensitivity to lipopolysaccharide and DNA microarray analysis of livers reveals an aberrant gene expression response. BMC Gastroenterol 2003;3:25.
38. Vasseur S, Folch-Puy E, Hlouschek V, et al. p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis-associated protein I. J Biol Chem 2004;279:7199-207. (Pubitemid 38248867)
39. Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 2002;129:2447-57. (Pubitemid 34863851)
40. Gommeaux J, Cano C, Garcia S, et al. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol 2007;27:2215-28. (Pubitemid 46418477)
41. Taieb D, Roignot J, Andre F, et al. ArgBP2-dependent signaling regulates pancreatic cell migration, adhesion, and tumorigenicity. Cancer Res 2008;68:4588-96.
42. Chirgwin JM, Przybyla AE, MacDonald RJ, et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5294-9. (Pubitemid 10140274)
43. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
44. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489-500.
45. Schreiber FS, Deramaudt TB, Brunner TB, et al. Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS (G12V) oncogene. Gastroenterology 2004;127:250-60. (Pubitemid 38962292)
46. Xia Y, Liu Y, Wan J, et al. Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem 2009;52:6083-96.
47. Xia Y, Liu Y, Rocchi P, et al. Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer. Cancer Lett 2012;318:145-53.
48. Gou S, Liu T, Wang C, et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas 2007;34:429-35. (Pubitemid 46725784)
49. Garcia-Montero AC, Vasseur S, Giono LE, et al. Transforming growth factor beta-1 enhances Smad transcriptional activity through activation of p8 gene expression. Biochem J 2001;357:249-53. (Pubitemid 32642923)
50. Pommier RM, Gout J, Vincent DF, et al. The human NUPR1/P8 gene is transcriptionally activated by transforming growth factor beta via the SMAD signalling pathway. Biochem J 2012;445:285-93.
51. Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 2012;22:194-207.
52. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11:1487-95.
53. Xia H, Cheung WK, Sze J, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J Biol Chem 2010;285:36995-7004.
54. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009;27:2059-68.
55. Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
56. Wang M, Xia Y, Fan Y, et al. A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells. Bioorg Med Chem Lett 2010;20:5979-83.
57. Garcia J, Ye Y, Arranz V, et al. IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation. EMBO J 2002;21:5151-63.
58. Letourneux C, Rocher G, Porteu F. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J 2006;25:727-38. (Pubitemid 43292435)
59. Sandi MJ, Hamidi T, Malicet C, et al. p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis. J Cell Physiol 2011;226:3442-51.
60. Collisson EA, Trejo CL, Silva JM, et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012;2:685-93.
61. Mohibi S, Mirza S, Band H, et al. Mouse models of estrogen receptor-positive breast cancer. J Carcinog 2011;10:35.
62. Zhao X, Gurumurthy CB, Malhotra G, et al. Breast cancer subtypes: two decades of journey from cell culture to patients. Adv Exp Med Biol 2011;720:135-44.
63. Mackay A, Weigelt B, Grigoriadis A, et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst 2011;103:662-73.
64. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602. (Pubitemid 41081385)